Ono Pharmaceuticals produces, purchases and sells pharmaceuticals and diagnostic reagents focusing primarily on prescription pharmaceuticals.
| Revenue (Most Recent Fiscal Year) | $3.20B |
| Net Income (Most Recent Fiscal Year) | $330.31M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | 15.41 |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 1.59 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.97 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 10.01 |
| Pre-Tax Margin (Trailing 12 Months) | 12.19% |
| Net Margin (Trailing 12 Months) | 10.24% |
| Return on Equity (Trailing 12 Months) | 6.20% |
| Return on Assets (Trailing 12 Months) | 4.66% |
| Current Ratio (Most Recent Fiscal Quarter) | 3.07 |
| Quick Ratio (Most Recent Fiscal Quarter) | 2.56 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.13 |
| Inventory Turnover (Trailing 12 Months) | 2.30 |
| Book Value per Share (Most Recent Fiscal Quarter) | $11.07 |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | -- |
| Diluted Earnings per Share (Trailing 12 Months) | $0.70 |
| Exchange | -- |
| Sector | -- |
| Industry | -- |
| Common Shares Outstanding | 469.71M |
| Free Float | -- |
| Market Capitalization | $5.07B |
| Average Volume (Last 20 Days) | 138.20 |
| Beta (Past 60 Months) | 0.49 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | -- |
| Percentage Held By Institutions (Latest 13F Reports) | 0.00% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |